One for All and All for One! The Expanding Role for PARP Inhibition in Ovarian Cancer

One for All and All for One! The Expanding Role for PARP Inhibition in Ovarian Cancer

View Activity

Activity Features


Downloadable Slides

Interactive Presentation

Activity Overview

This CME-certified webcast contains video and downloadable slides from the symposium One for All and All for One! The Expanding Role for PARP Inhibition in Ovarian Cancer, a prIME Oncology educational activity that was held in conjunction with the 2017 Progress and Controversies in Gynecologic Oncology Conference on 21 January 2017, in Barcelona, Spain.


Introduction: The current treatment landscape in advanced ovarian cancer
Andreas du Bois, MD, PhD

Key concepts of PARP inhibition
Christian Marth, MD, PhD

Practical guidance and strategies for PARP inhibition
Nicoletta Colombo, MD

prIME PointsTM
Andreas du Bois, MD, PhD


  • Andreas du Bois, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Nicoletta Colombo, MDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Christian Marth, MD, PhDInnsbruck Medical University
    Innsbruck, Austria

Target Audience

This meeting is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals, involved in the diagnosis and management of gynecologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity beyond BRCA mutations
  • Evaluate emerging data and ongoing clinical trials of maintenance therapy with PARP inhibitors in ovarian cancer and decide when to integrate the use of PARP inhibition into clinical practice
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and Disclosure Information


This educational activity is supported by a grant from TESARO, Inc.

Activity Date

February 15, 2017

February 15, 2018